Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Life Sciences Industry Analysis

UpdatedJan 30, 2026
DataAggregated Company Financials
Companies7
  • 7D-2.4%
  • 3M0.8%
  • 1Y-9.1%
  • YTD4.2%

Over the last 7 days, the Life Sciences industry has remained flat, although notably Siegfried Holding gained 10%. As for the longer term, the industry has declined 5.5% in the last year. Earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 30 Jan 2026CHF 51.1bCHF 10.6bCHF 1.1b33.5x46.5x4.8x
Sun, 28 Dec 2025CHF 48.9bCHF 10.6bCHF 1.1b29.7x44.5x4.6x
Tue, 25 Nov 2025CHF 48.1bCHF 10.6bCHF 1.1b27.7x43.8x4.5x
Thu, 23 Oct 2025CHF 50.9bCHF 10.6bCHF 1.1b30.2x46.3x4.8x
Sat, 20 Sep 2025CHF 51.0bCHF 10.6bCHF 1.1b34.3x46.3x4.8x
Mon, 18 Aug 2025CHF 52.8bCHF 10.7bCHF 1.1b36x46.7x4.9x
Wed, 16 Jul 2025CHF 52.5bCHF 10.1bCHF 1.0b32.8x50.5x5.2x
Fri, 13 Jun 2025CHF 54.2bCHF 10.1bCHF 1.0b33.1x52.2x5.4x
Sun, 11 May 2025CHF 53.8bCHF 10.1bCHF 1.0b31.1x51.8x5.3x
Tue, 08 Apr 2025CHF 44.8bCHF 10.1bCHF 1.0b27.1x43.7x4.4x
Thu, 06 Mar 2025CHF 54.9bCHF 10.1bCHF 1.0b30.6x52.6x5.4x
Sat, 01 Feb 2025CHF 56.6bCHF 10.1bCHF 1.0b36.4x56.2x5.6x
Mon, 30 Dec 2024CHF 52.9bCHF 10.2bCHF 943.4m35.6x56.1x5.2x
Wed, 27 Nov 2024CHF 53.6bCHF 10.2bCHF 943.7m40.6x56.8x5.3x
Fri, 25 Oct 2024CHF 56.1bCHF 10.2bCHF 943.5m42.2x59.4x5.5x
Sun, 22 Sep 2024CHF 55.1bCHF 10.2bCHF 943.1m42.7x58.5x5.4x
Tue, 20 Aug 2024CHF 57.2bCHF 10.2bCHF 914.5m46.1x62.5x5.6x
Thu, 18 Jul 2024CHF 54.6bCHF 10.3bCHF 1.0b47.4x54.5x5.3x
Sat, 15 Jun 2024CHF 51.8bCHF 10.3bCHF 1.0b44.3x51.7x5x
Mon, 13 May 2024CHF 55.2bCHF 10.3bCHF 1.0b44.3x55.1x5.4x
Wed, 10 Apr 2024CHF 57.1bCHF 10.3bCHF 1.0b45.9x57x5.6x
Fri, 08 Mar 2024CHF 51.9bCHF 10.2bCHF 982.0m47.9x52.9x5.1x
Sun, 04 Feb 2024CHF 46.5bCHF 10.2bCHF 1.0b41.3x45.7x4.6x
Tue, 02 Jan 2024CHF 41.9bCHF 9.8bCHF 1.5b32.5x28x4.3x
Thu, 30 Nov 2023CHF 40.4bCHF 9.8bCHF 1.5b30x27x4.1x
Sat, 28 Oct 2023CHF 36.6bCHF 9.8bCHF 1.5b25.6x24.5x3.7x
Mon, 25 Sep 2023CHF 46.5bCHF 9.8bCHF 1.5b32.2x31.2x4.8x
Wed, 23 Aug 2023CHF 51.4bCHF 9.7bCHF 1.5b35.5x34.5x5.3x
Fri, 21 Jul 2023CHF 57.0bCHF 9.7bCHF 1.6b35.3x34.9x5.9x
Sun, 18 Jun 2023CHF 59.2bCHF 9.7bCHF 1.6b38.2x36.3x6.1x
Tue, 16 May 2023CHF 61.6bCHF 9.7bCHF 1.6b39.7x37.7x6.4x
Thu, 13 Apr 2023CHF 60.5bCHF 9.7bCHF 1.7b42.7x36.2x6.2x
Sat, 11 Mar 2023CHF 55.9bCHF 9.6bCHF 1.7b32.6x33.6x5.8x
Mon, 06 Feb 2023CHF 58.0bCHF 9.6bCHF 1.6b33.7x35.5x6.1x
Price to Earnings Ratio

35.5x


Total Market Cap: CHF 58.0bTotal Earnings: CHF 1.6bTotal Revenue: CHF 9.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Life Sciences Industry Price to Earnings3Y Average 45.8x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Life Sciences industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 45.8x.
  • The industry is trading close to its 3-year average PS ratio of 5.2x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 12% per year over the last three years.
  • Meanwhile revenues for these companies have grown 3.7% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market-0.85%
Healthcare-1.35%
Life Sciences-2.45%
Clinical Research and Equipment-2.45%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SFZN Siegfried HoldingCHF 95.9010.1%
+CHF 385.2m		-6.3%PE27.2x
BANB Bachem HoldingCHF 71.050.5%
+CHF 26.2m		20.8%PE39.7x

Latest News

LONN
CHF 534.00
Lonza Group
7D
-3.8%
1Y
-9.6%
SFZN
CHF 95.90
Siegfried Holding
7D
10.1%
1Y
-6.3%
SKAN
CHF 57.70
SKAN Group
7D
-3.8%
1Y
-27.5%

SKAN: Medium Term Growth Commitments Will Offset Near Term Project Delays

Analysts have maintained their fair value estimate for SKAN Group at €70.33. They have made only minor adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, reflecting fine tuning rather than a change in their overall view.
PPGN
CHF 27.95
PolyPeptide Group
7D
-5.6%
1Y
5.5%

Metabolics Shift And New Capacity Will Support Long Term Peptide CDMO Opportunity

Catalysts About PolyPeptide Group PolyPeptide Group is a contract development and manufacturing partner focused on therapeutic peptides across development and commercial scales. What are the underlying business or industry changes driving this perspective?
TECN
CHF 136.00
Tecan Group
7D
-4.8%
1Y
-43.0%

TECN: Execution And CFO Transition Will Support Upgraded Outlook And Medium Term Upside

Narrative Update The analyst price target for Tecan Group has been revised to CHF 205 from CHF 200. Analysts cite updated assumptions on growth, profitability and a higher future P/E multiple as the main factors behind this change.
BANB
CHF 71.05
Bachem Holding
7D
0.5%
1Y
20.8%

BANB: Building K Execution Risks Will Limit Future Share Upside

Analysts have nudged their price target on Bachem Holding slightly lower to about CHF 60 to CHF 75, reflecting updated assumptions around discount rates, revenue growth near 21.5% and an expected future P/E close to 18.9%. They are also weighing recent research that includes a reduced CHF 60 target alongside a CHF 75 target tied to the company’s Building K expansion plans.
XLS
CHF 22.10
Xlife Sciences
7D
-8.3%
1Y
4.7%